STOCKHOLM — A large database analysis of more than 370,000 patients has found that glucagon-like peptide 1 (GLP-1) receptor agonists do not seem to increase the risk for diabetic retinopathy. The new findings, presented at the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, cast doubt on results from a pivotal clinical trial that …
